Altis Clinical Research Organisation Revenue and Competitors

Claim your profile

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Altis Clinical Research Organisation's estimated annual revenue is currently $22.3M per year.(i)
  • Altis Clinical Research Organisation's estimated revenue per employee is $201,000

Employee Data

  • Altis Clinical Research Organisation has 111 Employees.(i)
  • Altis Clinical Research Organisation grew their employee count by 37% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$36M17912%N/AN/A
#2
$34.4M17126%N/AN/A
#3
$47.2M23526%N/AN/A
#4
$23.9M119-27%N/AN/A
#5
$59.3M29542%N/AN/A
#6
$43.6M21713%N/AN/A
#7
$16.3M8121%N/AN/A
#8
$2.1M21-12%$114.3MN/A
#9
$8.4M42-7%N/AN/A
#10
$16.5M8228%N/AN/A

ALTIS is a contract research organization (CRO) providing pharmaceutical and biomedical industries with high-quality clinical services since 2001.

keywords:N/A

N/A

Total Funding

111

Number of Employees

$22.3M

Revenue (est)

37%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Altis Clinical Research Organisation News

2022-04-13 - Achievements & Awards

Swinburne University of Technology is a key partner organisation for the ... As the network grows, further clinical trials will be supported...

2019-09-08 - Super funds should back public housing: Flight Centre founder

Earlier this month First State Super partnered with private real estate funds management business Altis to lease 61 apartments in the Sydney ...

2019-09-07 - New pot law 'won't lead to monopoly'

... use of marijuana for medical and research purposes will not lead to a monopoly by large companies, and urged the public to study the law ...

2018-09-29 - NLA 'likely' to pass pot and kratom bill

A bill that would allow two narcotic plants, marijuana and kratom (Mitragyna speciose), to be grown for medical research purposes has been ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$20M11161%N/A
#2
$23.3M1116%N/A
#3
$36.4M11117%N/A
#4
$36.6M1117%N/A
#5
$13.3M111-21%N/A